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S U M M A R Y
Objectives: The early detection of drug resistance would be a boon for TB control programs. The aim of the
present study was to set up a rapid phage assay for the testing of drug susceptibility of Mycobacterium
tuberculosis to rifampin, isoniazid, ethambutol, streptomycin, and ciproﬂoxacin, directly on deconta-
minated sputum samples.
Methods: Mueller–Hinton broth was used instead of 7H9 broth to make the method more economical.
Vancomycin and polymyxin B were added to the concentrated sputum samples to reduce the bacterial
contamination. The phage assay on decontaminated sputum samples was compared with the proportion
method using M. tuberculosis isolates from the same sputum samples.
Results: Phage assay results were available within 48 h for rifampin and streptomycin and within 72 h
for all the other drugs. In contrast the proportion method required 4–6 weeks from the primary cultures.
The sensitivity of the phage assay was in the range of 93% to 100% and speciﬁcity in the range of 96% to
100% for all the drugs tested. The interpretation of results was possible for 334 of the 370 (90.3%) acid-
fast bacillus (AFB) smear-positive sputum samples by the phage assay.
Conclusions: The phage assay for the detection of drug resistance on direct decontaminated sputum
samples is economical, easy to perform, and rapid.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The World Health Organization (WHO) estimated that there
were 9.27 million new cases of tuberculosis (TB) worldwide in
2007.1 The countries with the highest prevalence were India (2.0
million cases), China (1.3 million), Indonesia (530 000), Nigeria
(460 000), and South Africa (460 000).1 The emergence of
multidrug-resistant (MDR)-TB, and more recently, extensively
drug-resistant (XDR)-TB, is a major threat to global TB control.2–5
MDR-TB, caused by strains resistant to at least isoniazid and
rifampin, is an alarming problem for the successful management of
global TB control programs, since it increases the cost of treatment
and the transmission risk, and lowers the cure rate.6 India is the
number one country in terms of TB prevalence, and the prevalence
rate of MDR-TB in the country is around 3% among new cases, 12%
among pretreatment cases,1 and an alarming 17% among patients
who have undergone previous treatment and who have developed* Corresponding author.
E-mail address: ds_chitnis@rediffmail.com (D.S. Chitnis).
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Russian Federation, were found to account for 62% of the estimated
global burden of MDR-TB cases.5 MDR-TB has been reported from
almost all parts of the world, primarily as a consequence of poor
and irregular treatment services, resulting in increased treatment
costs and also an increased risk of transmission of these resistant
strains of the bacilli.1 Also, the cure rate for MDR-TB is lower.
The early detection of MDR-TB could help in the effective
management of cases and in the overall TB control program.
However, current rapid phenotypic methods for assessing drug
susceptibility of M. tuberculosis, such as BACTEC, take 2–6 weeks after
laboratory isolation of the organisms. Rapid methods based on PCR
are considered an alternative approach for the detection of multidrug
resistance, but although there is conﬁdence in the detection of
rifampin resistance alone through the rpoB gene mutation,7–13
variations in resistance genes in isoniazid are problematic. Further,
the expensive set-up and a lack of expertise can be a hurdle for those
developing countries with a high burden of TB.
Mycobacteriophages are used as diagnostic markers to improve
and expedite the detection of viable mycobacteria in clinical
samples, as well as for the determination of drug resistance fromses. Published by Elsevier Ltd. All rights reserved.
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are now available for the detection of mycobacteria in clinical
samples.14–19 The phage-based assays depend on the ability of
resistant mycobacteria to support phage replication after being
exposed to drugs, while sensitive bacilli become inactivated and
hence are not able to support phage replication. Extracellular
phages are inactivated with a phagicidal agent, whereas intracel-
lular phages are protected and replicate, causing their lysis and the
release of a new phage progeny detected by the production of
plaques on a fast-growing Mycobacterium smegmatis (indicator
strain) lawn.
There are a few reports of phage-based assays carried out on
direct decontaminated sputum samples for the detection of
rifampin resistance, with fewer for isoniazid resistance. The
detection of multidrug resistance requires the determination of
resistance to both isoniazid and rifampin. Further, phage-based
assays for streptomycin, ethambutol, and ﬂuoroquinolones have
not been reported for direct sputum samples.
The purpose of this study was to evaluate an in-house and
standardized phage ampliﬁcation method using direct deconta-
minated sputum samples for the determination of rifampin,
isoniazid, ethambutol, streptomycin, and ciproﬂoxacin drug
resistance, and to compare the results to those acquired using
the gold standard proportion method.
2. Materials and methods
2.1. Population
Three hundred and seventy cases of acid-fast bacillus (AFB)
smear-positive pulmonary TB were referred to the Microbiology
Laboratory of Choithram Hospital and Research Centre (CHRC),
Indore, India during the period January 2008 to August 2010. Of
these cases, 62% were on anti-TB treatment and 40% had received
irregular treatment for more than 2 years and showed an
inadequate therapeutic response. The proportion of males was
65% and cases were aged in the range of 18–65 years.
The study was approved by the Research and Ethics Committee
of CHRC, Indore, India. The Ethics Committee has guidelines based
on the Declaration of Helsinki.
2.2. Samples
Sputum samples were collected in wide-mouth sterile contain-
ers. AFB smear by auramine O ﬂuorescent method was carried out on
the samples.20Prior to concentration, sputum samples were checked
for mycobacteria, and all 370 smear-positive samples were included
in the study. The density of AFB in the smear was recorded as per
WHO guidelines.21 Of the sputum samples included in the study, 52
were recorded as 1–3 AFB/100 high-power ﬁelds, 122 samples as 1+,
113 samples as 2+, and 83 samples as 3+.
The N-acetyl-L-cysteine–alkali digestion method, as described
by Kubica et al.,22 was used for the concentration of sputum
samples. After concentration, 5 units/ml polymyxin B (Samarth
Pharmaceutical Ltd, India) and 2 mg/ml vancomycin (Sigma, USA)
were added to prevent bacterial contamination.
2.3. Phage assay protocol
The phage assay protocol was developed for isoniazid, rifampin,
ethambutol, streptomycin, and ciproﬂoxacin drug susceptibility
testing directly on decontaminated sputum samples from pulmo-
nary TB cases.
All drugs were from Sigma-Aldrich Chemicals GmbH, Stein-
heim, Germany. Isoniazid, ethambutol, and streptomycin stock
solutions at 10 mg/10 ml were made in distilled water and ﬁlteredthrough a 0.2-m pore size membrane. Rifampin and ciproﬂoxacin
stock solutions (10 mg/10 ml) were made in dimethylformamide
(Sigma, USA). All the stock drug solutions were aliquoted and
preserved at 70 8C until use. The working solution was prepared
in Mueller–Hinton broth (BD Difco, USA; Cat. No. 275730) and had
no supplemented cation. The ﬁnal drug concentrations used were:
isoniazid 0.4 mg/ml, rifampin 2 mg/ml, ethambutol 16 mg/ml,
streptomycin 2 mg/ml, and ciproﬂoxacin 4 mg/ml. Plain Mueller–
Hinton broth without drug served as the control plate. Mueller–
Hinton agar (BD Difco, USA) supplemented with 0.4% glycerol and
1% glucose was used for plate pouring in the phage assay.
M. smegmatis mc2155 strain was used for the propagation of
mycobacteriophages on Mueller–Hinton agar. Mycobacteriophage
(D29) was propagated on M. smegmatis, as described by Sarkis and
Hatfull.23 The supernatant containing phages was passed through a
0.22-m millipore ﬁlter membrane and stored at 20 8C in a deep
freeze. The phage titer was determined using a standard spot test.
With regards to the drug exposure time period for M.
tuberculosis strains, decontaminated and concentrated sputum
samples were exposed to rifampin and streptomycin for 24 h,
while the exposure time for the other drugs was 48 h; this was
determined on the basis of our preliminary work and on other
studies.24–34
In brief, the assay was carried out in 10-ml plastic screw-capped
tubes (Nunc, USA). Five hundred microliters of decontaminated
sputum specimen was mixed with 500 ml of the drug. A wild-type
laboratory isolate drug-resistant strain and M. tuberculosis H37Ra
were included in all batches. Plain Mueller–Hinton broth without
drug served as the 0 mg/ml concentration of the drug. The tubes
were incubated for 24/48 h at 37 8C.
Two hundred microliters of mycobacteriophage D29 (108 pfu/
ml) were added to the respective tubes and incubated for 90 min at
37 8C. The extracellular phages were inactivated with 200 ml of
phagicidal agent ferrous ammonium sulfate (FAS; 30 mM) with a
contact time of 10 min. Next, the contents of the tubes were
transferred to tubes containing 10 ml Mueller–Hinton broth
(18  150 mm tubes) and the tubes vortexed to dilute the effect
of the FAS. Separate OADC (oleate–albumin–dextrose–catalase) or
citrate was not added as a neutralizing agent for FAS. One milliliter
of the broth mixture and 1 ml of M. smegmatis suspension was
dispensed into a sterile disposable Petri dish (90 mm); 10 ml of
molten Mueller–Hinton agar supplemented with glycerol and
glucose was added to the Petri dish and mixed by rotating
clockwise and anticlockwise. The plates were left for 10 min for
solidiﬁcation, transferred to an incubator at 37 8C, and left
overnight. Results were analyzed by counting the plaques. A
growth control containing no drug was included for each test
sample. The negative control plate had to have more than 100
plaques. If the plaque count was less, the experiment was repeated
with double the volume (1 ml) of decontaminated sputum sample.
The strains were considered resistant if the reduction in plaque
count was less than 80% for the drug compared to the ‘no drug’
control plate.
2.4. Drug susceptibility testing by proportion method
The proportion method was carried out on Lowenstein–Jensen
medium.35 The recommended critical concentrations of isoniazid
(0.2 mg/ml), rifampin (40 mg/ml), ethambutol (2 mg/ml), strepto-
mycin (4 mg/ml), and ciproﬂoxacin (2 mg/ml) were used.
2.5. Statistical analysis
Data were analyzed using Bayes Theorem and 2  2 contingen-
cy tables to calculate sensitivity, speciﬁcity, positive predictive
value (PPV), negative predictive value (NPV), and likelihood ratios
Table 1
The phage assay and its comparison with the proportion method for the detection of drug resistance to isoniazid, rifampin, streptomycin, ethambutol, and ciproﬂoxacin





























PPV NPV LR+ LR
INH 197 (59%) 196 1 137 (41%) 136 1 98 98 98 98 42 0.017
RIF 143 (43%) 143 0 191 (57%) 191 0 100 100 100 100 Inﬁnity 0.0
STR 183 (55%) 182 1 151 (45%) 151 0 98 100 100 98 Inﬁnity 0.017
EMB 106 (32%) 105 1 228 (68%) 226 2 97 97 94 99 34 0.031
CIP 93 (28%) 91 2 241 (72%) 238 3 93 96 90 97 23 0.069
AFB, acid-fast bacillus; TB, tuberculosis; INH, isoniazid; RIF, rifampin; STR, streptomycin; EMB, ethambutol; CIP, ciproﬂoxacin; PPV, positive predictive value; NPV, negative
predictive value; LR+, positive likelihood ratio; LR, negative likelihood ratio.
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ect, UK). The level of agreement between the phage assay and the
proportion method for the detection of drug resistance in M.
tuberculosis was measured using the kappa index (k) of agreement.
3. Results
Three hundred and seventy AFB-positive sputum samples were
selected for the phage assay. The density of AFB in the sputum
samples was 1–3 AFB/100 high-power ﬁelds in 52 samples, 1+ in
122 samples, 2+ in 113 samples, and 3+ in 83 samples.
The results of the phage assay and its comparison to the
proportion method are shown in Table 1.
After decontamination, the sputum samples were subjected to
the phage assay and culture. The phage assay was carried out on
the direct decontaminated sputum samples, whereas the propor-
tion method was carried out on the culture isolated from the same
sputum sample.
By the proportion method on the mycobacterial isolates,
mycobacterial resistance to isoniazid was found in 197 (58%), to
rifampin in 143 (43%), to streptomycin in 183 (55%), to ethambutol
in 106 (32%), and to ciproﬂoxacin in 93 (28%). The 143
mycobacterial isolates that were resistant to rifampin were also
resistant to isoniazid. In addition 54 samples showed resistance to
isoniazid but were sensitive to rifampin.
Concordance of the phage assay was 99.5% for isoniazid, 100%
for rifampin, 99.4% for streptomycin, 99.4% for ethambutol, and
97.8% for ciproﬂoxacin. Discordance was seen for two, nil, one,
three, and ﬁve samples in the case of isoniazid, rifampin,
streptomycin, ethambutol, and ciproﬂoxacin, respectively.
The sensitivity of the phage assay for isoniazid was 98%, for
rifampin was 100%, for streptomycin was 98%, for ethambutol was
97%, and for ciproﬂoxacin was 93% (Table 1). The speciﬁcity,
positive predictive value, and likelihood ratios are given in Table 1.
The level of agreement between the phage assay and the
proportion method was measured using Cohen’s kappa index (k) of
agreement: for isoniazid this was 0.9877 (standard error (SE)
0.0546), for rifampin 1.000 (SE 0.0547), for streptomycin 0.994 (SE
0.0546), for ethambutol 0.9795 (SE 0.0545), and for ciproﬂoxacin
0.9636 (SE 0.0543).
Seventeen of the 370 AFB smear-positive samples did not yield
growth on Lowenstein–Jensen medium and failed to give plaques
in the phage assay. Thirteen of the 370 sputum samples showed
bacterial/fungal contamination on the phage assay plates and did
not give interpretable results. Seventeen samples had fewer than
100 plaques on the phage assay plates. Hence, the experiment was
repeated using 1 ml volume of decontaminated sample, and
interpretable results were obtained in 11 cases. The plaque count
was persistently less than 100 on the negative control plates for six
samples and hence these could not be used for comparison.Interpretable results were obtained by the proportion method
for 95.4% of the samples, while the phage assay offered results for
90.3% of the samples. However, it should be mentioned that the
results were available within 48–72 h for the phage assay on the
direct samples, while the proportion method took 2–6 weeks after
the primary isolation.
4. Discussion
The conventional proportion method takes 4–6 weeks after the
isolation of M. tuberculosis. The PCR-based method offers results
within 8 h, however the set-up requires expensive equipment and
skilled personnel. Attempts are now being made by international
agencies to make the Xpert MTB/RIF test available in developing
countries.36 Further, molecular methodologies have gained cre-
dence only for the detection of rifampin resistance.7–13 A phage-
based assay was developed by Wilson et al. and was applied to
rifampin and isoniazid susceptibility testing in clinical isolates of
M. tuberculosis.37 Commercial phage-based assays are available
only for the detection of resistance to rifampin.14,38,39
A number of research papers have documented the utility of the
technique for the determination of drug resistance in mycobacte-
rial isolates.24–34 The approach was used by Albert et al.40 for the
detection of rifampin resistance in M. tuberculosis cells directly
from sputum samples.
Today the increase in multiple drug resistance appears to be a
worldwide problem, limiting the success of TB control programs,
and is one of the major challenges for the directly observed therapy
(DOT)-plus program. A recently updated meta-analysis describes
ﬁve publications on the detection of rifampin resistance on direct
decontaminated sputum samples.41 However, there are no
published data to support the use of phage assays for the detection
of isoniazid, ethambutol, streptomycin, and ciproﬂoxacin resis-
tance on direct clinical samples. Hence, the aim of the present
study was to standardize an in-house phage assay to determine
resistance to all of the ﬁrst-line anti-TB drugs (isoniazid, rifampin,
streptomycin, and ethambutol), and also to ﬂuoroquinolones,
directly on decontaminated sputum samples. Fluoroquinolones
are widely used along with other anti-TB drugs in India and
therefore were also included in the present study.
Middlebrook 7H9 medium was replaced with Mueller–Hinton
broth to make the assay economical. The cost of the commercial
phage-based assay (FASTPlaque TB-RIF, Biotec Laboratories Ltd,
UK) for rifampin resistance is approximately US$ 10 per test, while
the cost of consumables for the in-house phage-based assay is less
than US$ 1 per sample.
Seventeen of the 370 sputum samples failed to yield plaques in
the phage assay and also did not show growth on Lowenstein–
Jensen medium, indicating a lack of viable mycobacteria in the
samples. For seven of the samples (not shown in the results), the
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other 10 cases were on anti-TB drugs. The other limitation for a few
of the samples was the problem of contamination. Mole et al.
reduced the possibility of bacterial contamination from 14.3% to
0.8% by the use of nystatin, oxacillin, and aztreonam.42 In the
present study, a combination of polymyxin B and vancomycin was
used due to the high prevalence of methicillin-resistant Staphylo-
coccus aureus and extended-spectrum beta-lactamase producers in
the local setting, but still 13 of 370 samples (3.5%) failed to give
interpretable results on account of bacterial contamination.
To overcome the problem of a low plaque count in the 17
samples, the samples were reprocessed using 1 ml instead of
0.5 ml of decontaminated sputum sample, and 11 of them then
gave interpretable results. However, six still yielded low plaque
counts. The observation suggests phage inhibitory effects of
substances present in the sputum samples, as mentioned by
Albert et al.40 and Muzaffar et al.17 The possibility of a low density
of viable mycobacteria in the sputum samples also needs to be
considered.
In the present study contaminated results were seen in 13 and
indeterminate results in six, i.e., only 19/370 (5.1%) specimens. The
studies by Butt et al.,34 Albert et al.,40 and Mole et al.,42 reported
17–36% samples as contaminated/indeterminate by the phage
assay. The improved performance in the present study appears to
be due to the inclusion of vancomycin and polymyxin and the
performance of the in-house assay at our end. It should be
mentioned that the other studies reported only rifampin resistance
and did not include other drugs (isoniazid, streptomycin,
ethambutol, and ciproﬂoxacin).
The overall results based on sensitivity, speciﬁcity, negative and
positive predictive values, likelihood ratios (LR), and agreement
with the comparator based on the kappa value are good in the
present study (Table 1). The results were interpretable for 334/370
(90.3%) of the samples and were available in 48–72 h against an
average period of 4–6 weeks of primary culture by the proportion
method. The cost per test for isoniazid, rifampin, streptomycin,
ethambutol, and ciproﬂoxacin sensitivity testing by the in-house
phage assay was less than US$ 1. The commercially available
FASTPlaque method costs approximately US$ 10 per test and has
been standardized only for the detection of rifampin resistance for
decontaminated sputum samples.40 The use of Mueller–Hinton
broth and agar in the present study is far more economical than the
7H11 used in the FASTPlaque assay.
The threshold for deﬁning susceptibility was more than 80% for
all the drugs in the present study. However, a more than 99%
reduction in plaque count was observed for rifampin and
streptomycin, and this appeared to be due to high and rapid
bactericidal activity of the drugs for mycobacteria. This observa-
tion is consistent with the data from another mycobacteriophage-
based assay, the luciferase-reporter phage (LRP) assay, in which a
99% reduction in the light signal was seen after an overnight
incubation of susceptible isolates with streptomycin.43 These two
drugs required a shorter time exposure – 24 h – compared to the
other drugs, which required 48 h exposure in the present method,
and the reason appears to be the rapid bactericidal activity of
rifampin and streptomycin. Similar exposure times were observed
in another study.24 The mode of action of the drug may also be a
contributory factor, e.g., activity at the transcription/translation
level (streptomycin, rifampin) and at the cell wall level (e.g.,
isoniazid, ethambutol), as suggested by Jacobs et al.44
In the case of streptomycin and rifampin, the drug concentra-
tion required for exposure in the phage assay was less than the
recommended concentration for the proportion method and this
also appears to be due to the rapid bactericidal activity of the drugs.
The concentrations of the other drugs used in the study were
higher than recommended for the proportion method, possiblybecause of slower drug activity. In the proportion method a lower
concentration may sufﬁce since the exposure is over a long period.
The phage assay offers a simple and rapid testing method for the
detection of mycobacterial resistance using direct clinical speci-
mens like sputum, and could be a boon for the DOT-Plus program
in economically developing countries where the burden of TB is
very high. The methodology does not demand expensive equip-
ment. Our laboratory is presently working to standardize the
phage assay for other anti-TB drugs and the preliminary results are
very encouraging. The rapidity of the results and the cost-
effectiveness of the method is expected to offer great help in
reducing the transmission of drug-resistant TB infections and in
the effective management of MDR-TB cases.
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